Related Experiment Video
Updated: May 8, 2026
04:59
Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
Umeclidinium in patients with COPD: a randomised, placebo-controlled study
Roopa Trivedi1, Nathalie Richard, Rashmi Mehta
1GlaxoSmithKline, Research Triangle Park, NC, USA.
The European Respiratory Journal
|August 17, 2013
Summary
Umeclidinium significantly improved lung function and reduced dyspnea in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD). This 12-week study found the medication well-tolerated with a low incidence of adverse events.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a progressive lung disease.
- Effective long-term management of COPD symptoms is crucial for patient quality of life.
Purpose of the Study:
- To evaluate the efficacy and safety of umeclidinium in a dry powder inhaler for COPD.
- To assess the impact of umeclidinium on lung function, dyspnea, and health status.
Main Methods:
- A 12-week, randomized, placebo-controlled study.
- Participants received once-daily umeclidinium (62.5 or 125 μg) or placebo.
- Primary endpoint: change in trough forced expiratory volume in 1 second (FEV1) at day 85.
Main Results:
- Umeclidinium significantly improved trough FEV1 at day 85 (p<0.001).
- Significant improvements were observed in weighted mean FEV1, serial FEV1, transitional dyspnea index, and St. George's Respiratory Questionnaire scores.
- Adverse event incidence was low and comparable across treatment groups.
Conclusions:
- Umeclidinium demonstrated significant efficacy in improving lung function and health status in COPD patients.
- The medication was well-tolerated over the 12-week treatment period.
- Umeclidinium offers a safe and effective treatment option for COPD management.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History